The FDA has accepted for review the New Drug Application for SYD-101 (atropine sulfate) to slow the progression of myopia in children.
The survey included a national sample of 999 physicians. It found that 86% of respondents, even those who do not work ...
Although current federal budget considerations create much uncertainty concerning future Medicaid funding and program changes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results